MIRM•benzinga•
FDA Approves Mirum Pharma's Livmarli Tablet Formulation For Treatment Of Cholestatic Pruritus In Patients With Alagille Syndrome And Progressive Familial Intrahepatic Cholestasis
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 14, 2025 by benzinga